Subharmonic Contrast Ultrasound for Improved Characterization for Adnexal Masses-A Pilot Study
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Diagnostic Accuracy of Subharmonic Ultrasound Imaging Compared to Standard Ultrasound or Contrast Enhanced Magnetic Resonance Imaging (MRI)
研究概览
简要总结
This pilot clinical trial studies how well contrast-enhanced subharmonic ultrasound imaging works in improving the characterization of adnexal masses in patients undergoing surgery. Contrast-enhanced subharmonic ultrasound imaging uses high-frequency sound waves to produce images of internal organs and when combined with an ultrasound agent such as perflutren lipid microspheres, may help improve imaging and management of adnexal masses.
详细描述
PRIMARY OBJECTIVES:
I. To develop qualitative subharmonic imaging (SHI) or SHI-derived quantitative biomarkers.
II. To generate pilot data for a study to evaluate if they improve the characterization of benign and malignant adnexal masses compared to standard ultrasound or contrast enhanced magnetic resonance imaging (MRI) or the risk of malignancy index (RMI).
SECONDARY OBJECTIVES:
I. To compare the SHI depiction of adnexal masses' neovascularity in humans to intra-tumoral microvascular density (iMVD) obtained from CD31 an immunohistochemical marker of angiogenesis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Be diagnosed with an adnexal mass
- •Be scheduled for surgery to remove the adnexal mass
- •Be clinically stable
- •If a female of child-bearing potential, must have a negative pregnancy test
- •Be conscious and able to comply with study procedures
- •Have read and signed the Institutional Review Board (IRB)-approved informed consent form for participating in the study
排除标准
- •Females who are pregnant or nursing
- •Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours (h) afterwards
- •Patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts
- •Patients with pulmonary hypertension or unstable cardiopulmonary conditions
- •Patients currently on chemotherapy or with other primary cancers requiring systemic or hepatic loco-regional treatment
- •Patients who are clinically unstable, patients who are seriously or terminally ill with a life expectancy of less than 1 month, and patients whose clinical course are unpredictable; for example:
- •Patients on life support or in a critical care unit
- •Patients with unstable occlusive disease (e.g., crescendo angina)
- •Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia
- •Patients with uncontrolled congestive heart failure (New York Heart Association [NYHA] class IV)
- •Patients with recent cerebral hemorrhage
- •Patients who have undergone surgery within 24 hours prior to the study sonographic examination
- •Patients with a history of anaphylactic allergy to Definity, manifested by one or more of the following symptoms: generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, or shock
- •Patients with congenital heart defects
- •Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli
- •Patients with respiratory distress syndrome
- •Patients with thrombosis within the splenic vein
研究组 & 干预措施
contrast-enhanced subharmonic ultrasound imaging
Patients receive perflutren lipid microspheres IV. After 15 minutes, patients receive perflutren lipid microspheres IV again over 5 minutes and undergo contrast-enhanced subharmonic ultrasound imaging over 60 minutes.
干预措施: Perflutren Lipid Microspheres (Drug)
contrast-enhanced subharmonic ultrasound imaging
Patients receive perflutren lipid microspheres IV. After 15 minutes, patients receive perflutren lipid microspheres IV again over 5 minutes and undergo contrast-enhanced subharmonic ultrasound imaging over 60 minutes.
干预措施: Contrast-Enhanced Subharmonic Ultrasound Imaging (Procedure)
结局指标
主要结局
Diagnostic Accuracy of Subharmonic Ultrasound Imaging Compared to Standard Ultrasound or Contrast Enhanced Magnetic Resonance Imaging (MRI)
时间窗: Baseline scan to day of surgery
The techniques will be compared using an analysis of variance (ANOVA) method (i.e., baseline ultrasound imaging, SHI, or MRI) as the dependent variable and outcome as the independent variables. Diagnostic accuracy of lesion identification as "no lesion seen", "definitely benign", "indeterminate" or "definitely malignant" based on independent reads by experience radiologists for SHI with and without contrast vs contrast-enhanced MRI (quantitative analysis). For qualitative analysis, digital images from the SHI imaging were reviewed by the independent radiologists for interpretation. Diagnostic accuracy reported as percentage of lesions correctly identified through SHI as compared to ultrasound or MRI as the gold standard.
Accuracy of SHI Characterization Compared to the Risk of Malignancy Index
时间窗: Baseline scan to day of surgery
The ability of SHI to accurately characterize lesions as benign from malignant masses as compared to other imaging (ultrasound or MRI) and pathology will be analyzed using logistic regression and receiver operating characteristic (ROC) analyses.
次要结局
未报告次要终点
研究者
Flemming Forsberg
Professor - Radiology
Thomas Jefferson University